Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission

Ali, RIDVAN; Ozkalemkas, F; Ozcelik, T; Ozkocaman, VİLDAN; Ozan, U; Kimya, Y; Koksal, FATMA; Gulten, T; Yakut, T; Tunali, A

doi:10.1016/j.leukres.2005.01.009

Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission

Copy For Citation

Ali R., Ozkalemkas F., Ozcelik T., Ozkocaman V., Ozan U., Kimya Y., ...More

LEUKEMIA RESEARCH, vol.29, no.8, pp.971-973, 2005 (SCI-Expanded)

Publication Type: Article / Article
Volume: 29 Issue: 8
Publication Date: 2005
Doi Number: 10.1016/j.leukres.2005.01.009
Journal Name: LEUKEMIA RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.971-973
Keywords: chronic myelogenous leukemia, pregnancy, imatinib, MANAGEMENT
Bursa Uludag University Affiliated: Yes

Abstract

Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatimb and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation. (c) 2005 Elsevier Ltd. All rights reserved.